Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

¹Sorbonne Université, UPMC Univ Paris 06, Paris, France.
²Cancer Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
³Hôpital Avicenne, Assistance Publique—Hôpitaux De Paris, Bobigny, Service D'H ematologie Biologique, France.
⁴Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
⁵Dept of Pathology, School of Medicine, University of Otago, Dunedin, New Zealand.
⁶Children's Medical Research Institute, University of Sydney, Westmead NSW, Australia.
⁷Department of Gynecology and Obstetrics, Innsbruck Medical University, Innsbruck, Austria.
⁸Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.
⁹Department of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
¹⁰Service d'hématologie séniors, Hôpital St Louis/Université Paris 7, 1 avenue Claude Vellefaux, Paris, France.
¹¹Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
¹²Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
¹³Karolinska Institute, Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska University Hospital, Stockholm, Sweden.
¹⁴Bergonié Cancer Institute University of Bordeaux 229 cours de l'Argonne 33076 Bordeaux, France.
¹⁵Molecular Oncology Unit, Hospital Saint Louis, Paris, France.
¹⁶Cancer Genetics Program, Magee Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
¹⁷Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
¹⁸Department of Pathology, Stony Brook University, Stony Brook, New York.
¹⁹The University of Texas MD Anderson Cancer Center, Houston, Texas.
²⁰Department of Oncology, Division of Cancer Predisposition, St. Jude Children's Research Hospital, Memphis, Tennessee.
²¹Masaryk University, CEITEC – Molecular Medicine and University Hospital Brno, Department of Internal Medicine – Hematology and Oncology, Brno, Czech Republic.
²²Universidade Federal do Rio Grande do Sul (UFRGS) e Serviço deGenética Médica-HCPA, Rua Ramiro Barcelos, Porto Alegre, Brasil.
²³Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
²⁴The University of Texas MD Anderson Cancer Center, Houston, Texas.
²⁵Departments of Medicine and Human Genetics, McGill University and Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
²⁶Molecular Oncology Group, Department of Obstetrics and Gynaecology, Medical University of Vienna, Vienna, Austria.
²⁷University of Heidelberg, Department of Medicine V, Heidelberg, Germany; Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center (dkfz), Heidelberg, Germany.
²⁸Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
²⁹Generade Centre of Expertise Genomics and University of Applied Sciences Leiden, Leiden, the Netherlands.
³⁰Institut Albert Bonniot, Inserm 823, Université Grenoble Alpes, Rond Point de la Chantourne, La Tronche, France.
³¹Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, Stockholm, Sweden.
³²INSERM, U1138, Centre de Recherche des Cordeliers, Paris, France.

↵*Corresponding Author:
Thierry Soussi, Karolinksa Institutet, Cancer Centrum Karolinska, Stockholm 17176, Sweden and Sorbonne Université, UPMC Univ Paris 06, Paris, France. Phone: 46-8-5177-733. E-mail: thierry.soussi{at}ki.se or thierry.soussi{at}upmc.fr